Combination Immunotherapy Strategies in Melanoma: Insights From Key Trials

Source: CancerNetwork, May 2025

Panelists discuss how 2 key clinical trials, Checkmate 067 and RELATIVITY-047, established the efficacy of different immunotherapy combinations while highlighting the significant difference in toxicity profiles between ipilimumab plus nivolumab (60% grade 3/4 toxicity) versus relatlimab plus nivolumab (19% grade 3/4 toxicity).

Comparing Combination Immunotherapy Options

Key Discussion Points:

• Two major combination therapy options: nivolumab plus ipilimumab (CheckMate 067) and nivolumab plus relatlimab (RELATIVITY-047)
• Different primary end points and toxicity profiles between the 2 pivotal trials
• Indirect treatment comparison analysis suggests similar efficacy between the combinations

READ THE ORIGINAL FULL ARTICLE